Cardiogen 20mg Peptide
For in-vitro laboratory research only. Not for human or animal administration.
Batch #: VPCR20100
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Batch-specific Certificates of Analysis available for all products.
Cardiogen 20mg: overview
What the vial contains and what the material is, stated as specifications rather than as outcomes.
Cardiogen supplied as a lyophilized powder in a sealed single-use vial containing 20 mg of material. Cardiogen: molecular weight 489.5 g/mol. Released to a specification of >99% purity by HPLC. Soluble in bacteriostatic water. Supplied for in-vitro laboratory research only. Not a drug, food or supplement. Not for human or veterinary use.
Volta does not provide dosing, administration or protocol guidance for any material listed.
Cardiogen 20mg specifications
Every field the product record holds. A field with no value is omitted rather than printed as a dash.
- Fill
- 20mg
- Form
- Lyophilized powder
- Molecular weight
- 489.5 g/mol
- Solubility
- Soluble in bacteriostatic water
- Shelf life
- 24 months from date of manufacture
Cardiogen analytical verification and batch documentation
What the purity figure on this page is, who measured what, and which of the two a reader is looking at.
Specification. Every batch is released to >99% purity by HPLC. That is a threshold Volta sets, and it is a promise rather than a measurement.
Measurement. No certificate for this compound is published on the site yet. A batch-specific Certificate of Analysis is available on request, and the batch history lists the ones already published. Until one is published for this material, the figure above is the release specification and nothing on this page is a laboratory result.
Checking a certificate. The batch number printed beside the price is derived from the compound code and the vial strength; the lot number on a certificate is transcribed from the document. They are produced independently, so comparing them is a real check. How to read one is set out in the quality and testing methodology page.
For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease.
Cardiogen is the cardiac member of the Khavinson short peptide series, following the same tissue-specific logic as Epithalon for the pineal gland and Cortagen for the cortex. The proposed mechanism is direct interaction with promoter regions to modulate tissue-specific transcription, a claim that rests largely on molecular docking work and Russian-language experimental literature. Independent replication is limited, so it is best positioned as an exploratory research material. This 20mg vial is the standard presentation for the AEDR tetrapeptides.
- Released to a >99% purity specification by HPLC
- Lyophilized powder, 20mg per vial
- Soluble in bacteriostatic water
- For laboratory research use only
Frequently Bought Together
Cardiogen 20mg
20mg
$69 USD
Bundle & Save
$104 USD
Save $5.20 USD
$150 USD
Save $15 USD
$219 USD
Save $32.85 USD
$293 USD
Save $58.60 USD
Click any product above to toggle selection
Related research materials
Cardiogen 20mg: what is in the vial
The arithmetic specific to this 20mg vial, and what a milligram of Cardiogen costs in each strength the catalogue carries. Concentrations are stated, not recommended.
Vial contents
20 mg
Lyophilised powder, reconstituted by the buyer
Cost of material
$3.45 / mg USD
CA$4.95 / mg in Canadian dollars
Concentration at each diluent volume
20 mg of dry material reaches these concentrations in the volumes below. A U-100 syringe marking is 0.01 ml by definition, so the last column is a unit conversion at each concentration rather than a quantity to use.
| Diluent added | Concentration | In 0.1 ml | Per U-100 unit |
|---|---|---|---|
| 1 ml | 20 mg/ml | 2 mg | 200 mcg |
| 2 ml | 10 mg/ml | 1 mg | 100 mcg |
| 3 ml | 6.67 mg/ml | 666.7 mcg | 66.7 mcg |
| 5 ml | 4 mg/ml | 400 mcg | 40 mcg |
For a volume this table does not list, the reconstitution calculator takes any vial size and diluent volume.
Cardiogen purity and identity: how the figure is measured
What >99% (HPLC) means, the masses an identity check has to land on, and the entries that make a certificate of analysis checkable rather than decorative.
Stated purity
>99% (HPLC)
Area percent of the main peak by reversed-phase HPLC
Average mass
489.5 g/mol
The figure an identity check has to land on
Detection
214 nm
Identity by mass: the ions to expect
An electrospray source protonates the molecule rather than weighing it neutral, so a spectrum shows a series of charge states rather than the molecular weight itself. These are the m/z values 489.5 g/mol produces, and they are what a mass spectrum on a certificate for Cardiogen has to match.
| Ion | Charge | Expected m/z |
|---|---|---|
| [M+H]+ | 1+ | 490.51 |
Why 214 nm
The sequence carries neither tryptophan nor tyrosine, so it has no absorbance at 280 nm. Detection is at 214 nm, on the peptide bond itself.
This matters when reading someone else's certificate: a purity figure quoted at 280 nm for a compound with no aromatic residue is measuring an absorbance the molecule does not have.
What a certificate for Cardiogen should carry
A purity percentage on its own is not checkable. These are the entries that make one verifiable, and their absence is the most common weakness in a research-peptide certificate.
The chromatogram, not only the number
A stated area percent with no trace behind it cannot be read for the shape of the main peak or for what eluted beside it. The HPLC interpreter walks through what a trace shows.
Net peptide content, separately from gross mass
A lyophilised peptide is a salt, usually of trifluoroacetic or acetic acid, plus residual water. The vial's stated milligrams are gross; net peptide content is the fraction of that mass which is the molecule. The two differ by ten to twenty percent routinely, and only one of them is what the price is per milligram of. The net peptide content calculator converts between them.
The counterion, named
Which salt form the powder is in changes the net content and the pH the powder dissolves at. A certificate that never names it leaves both unknowable.
Water content, by a stated method
Loss on drying and Karl Fischer titration give different numbers, and a water figure with no method attached cannot be compared with anyone else's.
A laboratory and a report identifier
Without both, nothing on the document can be traced back to the laboratory that issued it. The red flag checker lists the rest.
Batch certificates are published as page images in the certificate library. The source PDFs are never served: a certificate is the most forgeable document a supplier publishes, and an editable copy carrying an accredited laboratory's letterhead is worth more to a counterfeiter than to a customer.
Cardiogen storage and stability
Handling as the product record states it, followed by the degradation chemistry this particular sequence is and is not exposed to.
Handling
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
What holds up
The degradation routes this compound is not exposed to, which is as specific a fact as the ones it is.
No oxidation-labile side chain
no Met, Cys or Trp in the sequenceThe three residues that oxidise readily are all absent, so the most common degradation route for a research peptide does not apply to this one. Air in the vial headspace is not the risk here that it is for a methionine-containing compound.
No deamidation site
no Asn or Gln in the sequenceDeamidation is the slow clock on most reconstituted peptides, and it needs an asparagine or a glutamine to run. This sequence has neither, so time in solution does not convert it to a one-dalton-heavier, more acidic relative.
No ultraviolet chromophore
no Trp or Tyr in the sequencePhoto-oxidation of peptides runs mainly through the aromatic side chains, and this sequence has none. Storing in the dark remains good practice for the excipients and the diluent, but the molecule itself has no strong absorber for ultraviolet light to act on.
Net hydrophilic
GRAVY -2.42A negative grand average of hydropathy means the side chains are on balance polar, which is the profile that stays in solution rather than associating. Freeze-thaw cycles are still worth avoiding, but this compound is not one of the hydrophobic sequences that aggregate irreversibly at an ice front.
Solubility window
calculated pI 4, net charge -1 at pH 7A peptide is least soluble within about a pH unit of its isoelectric point, where it carries no net charge. This one is far enough from neutral that it holds a real charge in an ordinary diluent, which is what keeps it dissolved.
Derived from the primary sequence AEDR, calculated isoelectric point 3.97, GRAVY -2.425. Check the arithmetic with the peptide property calculator and the freeze-thaw estimator.
Cardiogen compared with NAD+ (Nicotinamide Adenine Dinucleotide) and Thymalin
Pharmacological class, half-life, evidence grade, competition status and cost per milligram, side by side.
| Compound | Class | Half-life | Evidence | WADA | Cheapest per mg |
|---|---|---|---|---|---|
| Cardiogenthis page | Cardiovascular / Anti-Aging | ~20-40 minutes | DAnimal/Preclinical Only | Not listed | $3.4520mg vial, out of stock |
| NAD+ (Nicotinamide Adenine Dinucleotide) | Anti-Aging / Telomere | ~30 minutes (IV plasma); intracellular NAD+ turnover ~6-10 hours | CEarly Human / Mixed Evidence | Not prohibited | $0.081,000mg vial, out of stock |
| Thymalin | Immune / Anti-Aging | ~30-60 minutes (short peptide complex) | CEarly Human or Mixed Evidence | Not listed | $4.2010mg vial, out of stock |
| Vesugen | Cardiovascular / Bioregulator | Not established in humans | DLimited Evidence | Not listed | $2.9520mg vial, out of stock |
| BPC-157 | Healing & Recovery | ~15 min IV (animal data); oral activity persists 24+ hours | CPhase I–II Clinical Trials | Prohibited | $4.6010mg vial |
Evidence grades and half-lives are as recorded in the compound database, which cites its own sources on each compound page. Per-milligram prices are the cheapest strength each compound is currently listed at, in US dollars, and an out-of-stock note means that figure is not purchasable today. Cross-trial comparisons of efficacy are not comparisons: no head-to-head trial exists for most of these pairs.
Cardiogen in Canada
Price in Canadian dollars, where the parcel ships from, and how long it takes.
Price in CAD
CA$99
The figure charged, not a converted estimate
Ships from
British Columbia
A domestic parcel, so no import clearance step
Transit
2 to 5 business days
After 1 to 2 business days of handling
Free standard shipping
Over CA$250
A bar set for this market, not converted from the US one
Cardiogen 20mg ships from British Columbia to Canadian addresses, so the parcel never crosses a border. That removes the failure a Canadian buyer of research peptides is usually weighing: an inbound international shipment can be held for import clearance or seized, and a domestic one has no clearance step to be held at.
Shipping is quoted live against the delivery address at checkout rather than estimated here, and both the standard and express tiers show their price and transit window before a payment method is chosen. The figure the page shows is the figure the rail charges: all three settlement rails price shipping through the same functions the quote does.
The Canadian figure above is not a loose conversion. Each product's US dollar base is chosen so that the live conversion lands on the Canadian shelf price set for this market, and the result is pushed up to a whole dollar rather than left carrying cents, so one figure serves the page, the feed and every payment rail. See the shipping policy for carriers and cut-off times, and the legal position on research peptides in Canada for the regulatory picture.
Cardiogen Mechanism of Action
Cardiogen is the tetrapeptide Ala-Glu-Asp-Arg, AEDR, one of a family of ultrashort peptides developed at the St Petersburg Institute of Bioregulation and Gerontology. The proposed mechanism is unusual among the compounds in this catalogue: rather than binding a cell surface receptor, these peptides are held to enter the cell and the nucleus and interact directly with DNA and with histone proteins, altering transcription of specific genes.
The family shares a structural core. Cardiogen is AEDR, cortagen is AEDP, and epithalon is AEDG: the same Ala-Glu-Asp tripeptide with a different fourth residue in each. The associated hypothesis is that the fourth residue shifts the sequence's complementarity to particular DNA sequences, which is what would give each peptide its reported tissue specificity, cardiac tissue in this case. That is a strong claim and it is a hypothesis rather than an established mechanism.
Uptake has been addressed more concretely. Work from the same group reports that these ultrashort peptides are carried into cells by peptide transporters of the POT family and by L-type amino acid transporters, rather than crossing membranes passively. Transporter-mediated uptake is a plausible and testable proposition, and it is the better-supported part of the mechanistic account.
Transporter-mediated uptake
Reported carriage into cells by POT family peptide transporters and L-type amino acid transporters rather than by passive diffusion.
Nuclear entry
The peptides are proposed to reach the nucleus, which is a prerequisite for the DNA interaction the model depends on.
DNA and histone interaction
Proposed direct interaction with DNA sequences and with histone proteins, altering chromatin accessibility and transcription.
Sequence-specific targeting
The hypothesis that the fourth residue determines which DNA sequences are engaged, and therefore which tissue responds. AEDR is assigned to cardiac tissue on this basis.
Altered gene expression
Reported changes in expression of signalling molecules and of genes associated with tissue function, which is the measured endpoint in most of this literature.
Cardiogen and Khavinson Peptide Research Findings
Almost all published work addresses the peptide family rather than AEDR specifically. Each entry names which peptide was actually studied, because the distinction is usually lost in secondary summaries.
Short peptides reported to regulate gene expression and protein synthesis
Work on the KE peptide reported regulation of SIRT1, PARP1 and PARP2 gene expression and protein synthesis in human mesenchymal cells, which is the clearest example of the transcriptional mechanism claimed for the family. Studied with KE, not AEDR.
In vitroTransport of ultrashort peptides characterised
A study of transport using POT and LAT carriers addressed how these peptides enter cells, which is the most mechanistically concrete part of the account and applies to the family as a class.
In vitroComparative effects of two family members on the same cell type
A comparison of KE and AED peptides on the functional activity of human skin fibroblasts is one of the few studies designed to distinguish family members from one another rather than treating them interchangeably.
In vitroEffects on signalling molecule expression in organotypic culture
Short peptides were reported to alter expression of signalling molecules in organotypic pineal cell cultures, an experimental system that preserves tissue architecture better than dissociated cells.
In vitroPeptide sequence identified within the human proteome
Work locating the KE peptide within the human proteome addressed whether these sequences occur naturally rather than being purely synthetic constructs, which bears on the plausibility of an endogenous regulatory role.
In vitroShort peptides altered interleukin-2 gene expression
Studies reported effects of short peptides on interleukin-2 messenger RNA synthesis in rat hypothalamic structures and on interleukin-2 gene expression in splenocytes, extending the transcriptional claims to immune signalling.
Rodent modelCardiogen Molecular Information
| Sequence | Ala-Glu-Asp-Arg |
| Single-letter Code | AEDR |
| Length | 4 amino acids |
| Molecular Formula | C18H31N7O9 |
| Molecular Weight | 489.5 g/mol, computed from the sequence |
| Family | Khavinson ultrashort peptide bioregulators |
| Shared Core | Ala-Glu-Asp, the same first three residues as cortagen (AEDP) and epithalon (AEDG) |
| Assigned Tissue | Cardiac, on the sequence-specificity hypothesis rather than on direct demonstration |
| Proposed Uptake | POT family peptide transporters and L-type amino acid transporters |
| Appearance | White lyophilised powder |
One Core, Four Residues, Four Claimed Tissues
The most striking feature of this family is how little separates its members. Cardiogen is AEDR, cortagen is AEDP, epithalon is AEDG. Three of four residues are identical and the peptides are assigned to cardiac, neural and pineal tissue respectively.
The hypothesis that carries that assignment is that the fourth residue changes the sequence's complementarity to DNA, so each peptide engages different promoter regions and therefore different tissues. It is a coherent proposal and it makes the family intellectually interesting rather than arbitrary.
It is also a very large claim resting on a very small structural difference, and the published work supporting tissue specificity at the level of individual family members is thin compared with the work supporting the general proposition that these peptides affect gene expression. A reader should hold the class-level claim and the member-level claim to different standards, because the evidence does.
Most of the Evidence Is About the Family, Not This Peptide
Searching the literature for AEDR specifically returns very little. Searching for Khavinson short peptides returns a substantial body of work, but it is dominated by KE, the dipeptide also called vilon, and by AEDG, epithalon.
That matters for anyone reading a product page. Findings obtained with KE or AEDG are routinely presented as evidence for cardiogen, and under the family's own hypothesis they should not be: the whole premise is that the differing residue changes which genes are engaged. If the peptides really are tissue-specific, their evidence is not interchangeable, and if their evidence is interchangeable, the specificity claim weakens.
The sources listed here name which peptide each study actually used, so that inference is left to the reader rather than made silently on their behalf.
A Literature That Is Real, Narrow and Largely Untranslated
This work is genuine peer-reviewed pharmacology published over several decades, mostly in Russian-language journals such as Advances in Gerontology and Bulletin of Experimental Biology and Medicine, and largely from one institute and its collaborators.
That is not a reason to dismiss it, and it is a different criticism from fabricated citations. It does mean the standard caveat about independent replication applies with unusual force, since findings repeated within a single research tradition are less robust than findings reproduced by groups with different assumptions, reagents and incentives.
There is no approved product containing AEDR in any Western jurisdiction and no controlled human efficacy trial. Material supplied for research is for in-vitro laboratory use only.
Handling and Analytical Considerations
A tetrapeptide of 489 daltons is at the small end of what peptide analytical methods handle comfortably. Retention on a standard reversed-phase column is short for such a polar sequence, with three ionisable side chains between the glutamate, aspartate and arginine, so a method developed for larger peptides may not retain it well enough to separate it from its impurities.
The family's members are also close in mass to one another, and AEDR at 489.5 differs from AEDP at 430.4 by about 59 daltons. That is resolvable, but for a supplier producing several family members a mass check is a worthwhile identity confirmation rather than a formality.
Cardiogen Research FAQ
Cardiogen in Summary
Cardiogen is the tetrapeptide AEDR from the Khavinson ultrashort peptide family, proposed to enter the nucleus and alter transcription by direct interaction with DNA rather than by receptor binding. Transporter-mediated uptake is the best-supported part of that account.
It differs from cortagen and epithalon by a single residue, and its assignment to cardiac tissue rests on the hypothesis that this residue determines DNA complementarity. Almost all published evidence concerns the family rather than AEDR itself.
Scientific References
Primary literature and public trial registries only. No supplier or retailer pages are cited.
- 1KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal cellsKhavinson VK, Linkova NS, et al. · Advances in Gerontology · 2023
- 2Transport of Biologically Active Ultrashort Peptides Using POT and LAT CarriersKhavinson V, Linkova N, Dyatlova A, et al. · International Journal of Molecular Sciences · 2022
- 3Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin FibroblastsFridman NV, Linkova NS, et al. · Bulletin of Experimental Biology and Medicine · 2020
- 4Effect of short peptides on expression of signaling molecules in organotypic pineal cell culturesKhavinson VKh, Linkova NS, et al. · Bulletin of Experimental Biology and Medicine · 2011
- 5Peptide KE in Human ProteomeTerekhov AY, Kormilets DY, et al. · Bulletin of Experimental Biology and Medicine · 2020
- 6Synthesis of IL-2 mRNA in cells of rat hypothalamic structures after injection of short peptidesKazakova TB, Barabanova SV, et al. · Bulletin of Experimental Biology and Medicine · 2005
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Cardiogen 20mg: frequently asked questions
Answered from the product record and the certificate file. Volta does not answer questions about administration, dosing or protocols.
What is supplied in a 20 mg vial of Cardiogen?
A sealed single-use vial containing 20 mg of Cardiogen as a lyophilized powder. Soluble in bacteriostatic water. No diluent, syringe or other supply is included.
Is Cardiogen supplied for human use?
No. For in-vitro laboratory research by qualified professionals only. Not for human or animal administration. Not a drug, food, cosmetic or dietary supplement. Not intended to diagnose, treat, cure, mitigate or prevent any disease. Volta does not provide dosing, administration or protocol guidance for any material listed.
What purity is this Cardiogen released to?
>99% by HPLC. That figure is a release specification, a threshold Volta sets for every batch, and it is not the same kind of statement as a purity measured by a named laboratory for a named lot.
Is there a certificate of analysis for this Cardiogen vial?
A batch-specific Certificate of Analysis is available for this product on request. It is not published on the site yet: the batch history on the quality page lists the certificates already published, and this vial is covered by the release specification until its own is added there.
How is Cardiogen identified?
molecular weight 489.5 g/mol. Those identifiers are what an incoming-goods check compares a certificate against, and they are stated here so the comparison can be made before ordering.
How should Cardiogen be stored before reconstitution?
Store lyophilized peptide at -20°C in a dry, dark environment. Reconstitute in bacteriostatic water. Once reconstituted, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles. Lyophilized powder is stable at room temperature for shipping and short-term storage.
Where does this ship from?
British Columbia, Canada. Canadian orders are domestic, so they clear no customs and pay no import duty. International orders ship from the same facility.
Explore Research
Peptide Tools
More from the research catalogue
Every compound below has its own specification, batch number and certificate page, whether or not a vial is in stock today. Supplied for laboratory research use only.
Related research compounds
- Cortagen 20mgrestocking
- Glutathione 1500mgrestocking
- Humanin 10mgrestocking
- LL-37 5mgrestocking
- KLOW 80mg